Tay R, P L, Pang S, Low K, Tay H, Ho C
Theranostics. 2024; 14(16):6138-6160.
PMID: 39431019
PMC: 11488102.
DOI: 10.7150/thno.95527.
Nose K, Taniguchi K, Fujita M, Moyama C, Mori M, Ishita M
Cancer Gene Ther. 2024; 31(12):1831-1839.
PMID: 39394529
DOI: 10.1038/s41417-024-00835-y.
Iyer V, Donahue J, Osman M
Cell Commun Signal. 2024; 22(1):477.
PMID: 39375741
PMC: 11457365.
DOI: 10.1186/s12964-024-01809-1.
Zhu C, Chen X, Liu T, Cheng L, Cheng W, Cheng P
Nat Commun. 2024; 15(1):8506.
PMID: 39353936
PMC: 11445535.
DOI: 10.1038/s41467-024-52888-0.
Vandecandelaere G, Ramapriyan R, Gaffey M, Richardson L, Steuart S, Tazhibi M
Cells. 2024; 13(17.
PMID: 39273050
PMC: 11394304.
DOI: 10.3390/cells13171480.
In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development.
Figg J, Chen D, Font L, Flores C, Jin D
Neuro Oncol. 2024; 26(11):1964-1980.
PMID: 38990913
PMC: 11534310.
DOI: 10.1093/neuonc/noae131.
A non-canonical role for a small nucleolar RNA in ribosome biogenesis and senescence.
Cheng Y, Wang S, Zhang H, Lee J, Ni C, Guo J
Cell. 2024; 187(17):4770-4789.e23.
PMID: 38981482
PMC: 11344685.
DOI: 10.1016/j.cell.2024.06.019.
STAT1-Deficient HPV E6/E7-Associated Cancers Maintain Host Immunocompetency against Therapeutic Intervention.
Lim L, Hu M, Fan D, Tu H, Tsai Y, Cheng M
Vaccines (Basel). 2024; 12(4).
PMID: 38675812
PMC: 11053987.
DOI: 10.3390/vaccines12040430.
Tumor microenvironment remodeling plus immunotherapy could be used in mesenchymal-like tumor with high tumor residual and drug resistant rate.
Shen S, Liu X, Guo Q, Liang Q, Wu J, Guan G
Commun Biol. 2023; 6(1):1281.
PMID: 38110614
PMC: 10728080.
DOI: 10.1038/s42003-023-05667-4.
Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues.
Slika H, Karimov Z, Alimonti P, Abou-Mrad T, De Fazio E, Alomari S
Int J Mol Sci. 2023; 24(22).
PMID: 38003507
PMC: 10671665.
DOI: 10.3390/ijms242216316.
Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J, Guo Q, Xing R
BMC Cancer. 2023; 23(1):727.
PMID: 37543576
PMC: 10403952.
DOI: 10.1186/s12885-023-11222-5.
H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas.
Garcia-Fabiani M, Haase S, Banerjee K, McClellan B, Zhu Z, McClellan B
bioRxiv. 2023; .
PMID: 37398299
PMC: 10312611.
DOI: 10.1101/2023.06.13.544658.
Myb Repression Mediates Stat5b-knockdown-induced Apoptosis and Inhibits Proliferation of Glioblastoma Stem Cells.
Moyama C, Fujita M, Okamoto H, Ii H, Nakata S
Cancer Genomics Proteomics. 2023; 20(2):195-202.
PMID: 36870690
PMC: 9989674.
DOI: 10.21873/cgp.20374.
SRSF3 and HNRNPH1 Regulate Radiation-Induced Alternative Splicing of Protein Arginine Methyltransferase 5 in Hepatocellular Carcinoma.
Wen C, Tian Z, Li L, Chen T, Chen H, Dai J
Int J Mol Sci. 2022; 23(23).
PMID: 36499164
PMC: 9738276.
DOI: 10.3390/ijms232314832.
Cancer cell intrinsic TIM-3 induces glioblastoma progression.
Guo Q, Shen S, Guan G, Zhu C, Zou C, Cao J
iScience. 2022; 25(11):105329.
PMID: 36325060
PMC: 9618784.
DOI: 10.1016/j.isci.2022.105329.
Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
Peng S, Xing D, Ferrall L, Tsai Y, Hung C, Wu T
J Biomed Sci. 2022; 29(1):80.
PMID: 36224625
PMC: 9554842.
DOI: 10.1186/s12929-022-00864-5.
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
Haase S, Banerjee K, Mujeeb A, Hartlage C, Nunez F, Nunez F
J Clin Invest. 2022; 132(22).
PMID: 36125896
PMC: 9663161.
DOI: 10.1172/JCI154229.
Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.
Schwark K, Messinger D, Cummings J, Bradin J, Kawakibi A, Babila C
Front Oncol. 2022; 12:922928.
PMID: 35978801
PMC: 9376238.
DOI: 10.3389/fonc.2022.922928.
Stat5b inhibition blocks proliferation and tumorigenicity of glioblastoma stem cells derived from a murine brain cancer model.
Moyama C, Fujita M, Ando S, Taniguchi K, Ii H, Tanigawa S
Am J Cancer Res. 2022; 12(3):1129-1142.
PMID: 35411230
PMC: 8984887.
Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.
Feng J, Lu H, Ma W, Tian W, Lu Z, Yang H
Protein Cell. 2022; 13(11):825-841.
PMID: 35217990
PMC: 9237198.
DOI: 10.1007/s13238-022-00906-6.